Related Experiment Video
Updated: Jan 9, 2026

PLGA Nanoparticles Formed by Single- or Double-emulsion with Vitamin E-TPGS
Published on: December 27, 2013
Release mechanisms of PLGA-based drug delivery systems: A review
1Univ. Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France.
Abstract:
Poly(lactic-co-glycolic acid) (PLGA)-based microparticles and implants are of continuously increasing importance as parenteral controlled drug delivery systems. However, the underlying drug release mechanisms are often not understood, rendering product optimization difficult: The effects of formulation and processing parameters on drug release can be surprising. Also, upscaling and troubleshooting during production at industrial scale can be highly cumbersome. This can be attributed to the complexity of the physicochemical processes, which can be involved in the control of drug release. Generally, tri-phasic drug release patterns are observed: An initial burst release is followed by a zero order release phase and a final, again, rapid release phase. The relative importance of the different phases can strongly depend on the: (i) composition (e.g., type & amount of drug and polymer), geometry and dimensions of the system, (ii) manufacturing procedure, and (iii) conditions in the surrounding environment (e.g., bulk fluid versus human tissue). Water penetration into the system, drug dissolution, limited solubility effects, drug diffusion through an "intact polymeric matrix" (polymer phase) and/or through water filled pores, pore closure due to local PLGA swelling, osmotic effects, polymer degradation, local drops in micro-pH, autocatalytic effects, substantial swelling of the entire system as well as other phenomena can be of importance. This article aims at giving an overview on the current knowledge in this field. Please note that it is hypotheses-driven, thus, general conclusions should be seen with caution. Also, each drug delivery system should be considered on a case-by-case basis. This article also aims at raising awareness on two aspects, which are often neglected: (i) Substantial system swelling is likely the root cause for the onset of the third drug release phase in many systems. (ii) In the case of microparticles, only looking at drug release from ensembles (hundreds of thousands/millions) of particles can be misleading.
Related Concept Videos
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Bioavailability Enhancement: Drug Permeability Enhancement
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Biopharmaceutical Factors Influencing Drug Product Design: Overview

